GlassScriptPhysician profile
Irena Gesheva
NPI 1326122508
$4,966.60
in general payments reported to CMS, 2019-2025
49 companies · $631 in 2025
The $631 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $309 · 2021: $804 · 2022: $1,128 · 2023: $609 · 2024: $803 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $575.97 | 2021-2025 | |
| Boston Scientific Corporation | $336.77 | 2020-2025 | Watchman Flx |
| Novo Nordisk INC | $311.39 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $291.27 | 2019-2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $271.22 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $251.68 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $240.48 | 2020-2024 | Trelegy Ellipta, Arexvy, Boostrix |
| Insmed, INC. | $227.45 | 2025 | Arikayce, Brinsupri |
| Ge Healthcare | $220.50 | 2019-2023 | |
| Lilly USA, LLC | $213.63 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Neurocrine Biosciences, INC. | $176.70 | 2021-2022 | |
| Abbott Laboratories | $162.99 | 2019-2021 | |
| Exact Sciences Corporation | $136.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $133.24 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.58 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irena Gesheva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.